These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8002320)
1. Double-blind trial of fluoxetine: chronic daily headache and migraine. Saper JR; Silberstein SD; Lake AE; Winters ME Headache; 1994 Oct; 34(9):497-502. PubMed ID: 8002320 [TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
3. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ; Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971 [TBL] [Abstract][Full Text] [Related]
4. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Krymchantowski AV; Silva MT; Barbosa JS; Alves LA Headache; 2002 Jun; 42(6):510-4. PubMed ID: 12167139 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J; Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356 [TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD; Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Cady RK; Saper J; Dexter K; Cady RJ; Manley HR Headache; 2015 Apr; 55(4):529-42. PubMed ID: 25828648 [TBL] [Abstract][Full Text] [Related]
8. The impact of topiramate on health-related quality of life indicators in chronic migraine. Dodick DW; Silberstein S; Saper J; Freitag FG; Cady RK; Rapoport AM; Mathew NT; Hulihan J; Crivera C; Rupnow MF; Mao L; Finlayson G; Greenberg SJ Headache; 2007; 47(10):1398-408. PubMed ID: 18052949 [TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197 [TBL] [Abstract][Full Text] [Related]
10. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543 [TBL] [Abstract][Full Text] [Related]
11. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study. Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341 [TBL] [Abstract][Full Text] [Related]
12. Fremanezumab for the Preventive Treatment of Chronic Migraine. Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818 [TBL] [Abstract][Full Text] [Related]
13. Fluoxetine and migraine: comparison of double-blind trials. Saper JR; Silberstein SD; Lake AE; Winters ME Headache; 1995 Apr; 35(4):233. PubMed ID: 7775182 [No Abstract] [Full Text] [Related]
14. A prospective randomized double blind placebo controlled crossover study of fluoxetine efficacy in the prophylaxis of chronic daily headache in children and adolescents. Gherpelli JL; Esposito SB Arq Neuropsiquiatr; 2005 Sep; 63(3A):559-63. PubMed ID: 16172700 [TBL] [Abstract][Full Text] [Related]
15. Effect of a traditional syrup from Citrus medica L. fruit juice on migraine headache: A randomized double blind placebo controlled clinical trial. Jafarpour M; Yousefi G; Hamedi A; Shariat A; Salehi A; Heydari M J Ethnopharmacol; 2016 Feb; 179():170-6. PubMed ID: 26721220 [TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF; Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892 [TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM; Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098 [TBL] [Abstract][Full Text] [Related]
19. Fluoxetine for migraine prophylaxis: a double-blind trial. d'Amato CC; Pizza V; Marmolo T; Giordano E; Alfano V; Nasta A Headache; 1999; 39(10):716-9. PubMed ID: 11279947 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]